STL Index for: Brian Berman

The Role of Imiquimod 3.75% Cream in the Treatment of External Genital Warts

Imiquimod 3.75% cream has recently been approved by both the FDA and Health Canada for the treatment of external genital warts. This article is an overview of EGW, phase 3 clinical trials leading to the approval of imiquimod 3.75% cream, and comparison with imiquimod 5% cream.

Immunological Strategies to Fight Skin Cancer

Skin cancer is the most common human cancer, and is currently considered a global epidemic. Recently, there has been a growing interest in immunomodulators, or upregulators of the immune response.

Novel Dermatologic Uses of the Immune Response Modifier Imiquimod 5% Cream

Imiquimod is the first of a new class of drugs to emerge in the treatment of various dermatologic disorders. As an immune response modifier, it has been shown to have potent antiviral and antitumor properties through the stimulation of innate and cell mediated immune pathways.

POPULAR